Sign in
Taking peoplePhase 3

Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage

Key facts

Who runs it
Beijing Tiantan Hospital
Where
China41 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
1,192 people, planned
Started
2 Apr 2026
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Minocycline hydrochloride capsules
  • Placebo capsules of Minocycline hydrochloride capsules
Record updated
23 April 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • CT-confirmed spontaneous supratentorial intracerebral hemorrhage
  • Aged 18 to 80 years
  • Within 48 hours of symptom onset
  • Hematoma volume 15-40 ml
  • NIHSS score 8-24, with item 1a ≤ 2
  • Signed informed consent by the patient or legal representative

Who cannot take part

  • Intracranial or spinal surgery within the past 3 months
  • Any major surgery or severe physical trauma within the past month
  • Secondary intracerebral hemorrhage (traumatic, tumor-related, vascular malformation, aneurysm, coagulation disorder, etc.)
  • Intraventricular hemorrhage filling one entire lateral ventricle, third ventricle, or fourth ventricle, or more than half of two lateral ventricles
  • Significant subarachnoid hemorrhage (Fisher grade ≥ 3) or subdural hemorrhage
  • Patients with uncontrollable hypertension ( systolic blood pressure persistently ≥ 180 mmHg despite intensive antihypertensive treatment)
  • Progressive neurological or other severe systemic diseases
  • Planned surgical intervention for the intracerebral hemorrhage
  • Pre-stroke disability (modified Rankin Scale score > 1)
  • Allergy or intolerance to minocycline or other tetracycline antibiotics
  • History of pseudomembranous enteritis or antibiotic-associated enteritis
  • Other conditions that are not suitable for participating in this clinical trial, such as inability to understand and/or follow the research procedures due to mental, cognitive, emotional, or physical disorders, etc
  • Severe cardiac insufficiency (NYHA Class III-IV), severe liver disease (ALT or AST > 3 times the normal upper limit value), severe renal insufficiency (serum creatinine > 2 times the normal upper limit value, or glomerular filtration rate < 45 ml/min), or malignancy with life expectancy < 1 year
  • Moderate to severe anemia (hemoglobin < 90 g/L), thrombocytopenia (platelet count < 100×10\^9/L), leukopenia (white blood cell count < 2×10\^9/L), or coagulopathy (INR > 1.5)
  • Use of tetracycline antibiotics within the past week
  • Females who are pregnant, within 30 days postpartum, or in the lactation period
  • Participated in other interventional clinical trials within the past 3 months
  • Inability to obtain signed informed consent from the patient or representative

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. It aims to evaluate the efficacy and safety of oral minocycline in patients with acute spontaneous intracerebral hemorrhage within 48 hours of onset.

The 2 groups in the trial

  • Active Comparator: Minocycline treatment groupTreatment being tested

    Minocycline Hydrochloride Capsules (50 mg per capsule). The first dose (200mg, 4 capsules) should be given immediately after randomization (within 30 minutes); Subsequently, 100mg (2 capsules) will be administered once every 12 hours; a total of 10 times (lasting 5 days; the subject with dysphagia will be administrated through a nasal feeding tube).

    Treatment: Minocycline hydrochloride capsules

  • Placebo Comparator: Minocycline placebo-control groupPlacebo, for comparison

    Placebo of Minocycline Hydrochloride capsules (50mg per capsule, containing 0 mg of Minocycline). The method of administration was the same as that of treatment group.

    Treatment: Placebo capsules of Minocycline hydrochloride capsules

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Minocycline in Patients With Acute Spontaneous Intracerebral Hemorrhage: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase III Trial
Criteria questions
Built from NCT07338175, who can take part
Record updated
23 April 2026